Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alissa Visram

Showing results (21-30 of 73) with videos related to

Pageof 8
Sort By:
Journal of Geriatric Oncology|July 21, 2023
Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysisJoanne Britto, Hsien Seow, Gregory R Pond, et al.
Blood Cancer Journal|April 27, 2023
An atlas of the bone marrow bone proteome in patients with dysproteinemiasMatthew Ho, Surendra Dasari, Alissa Visram, et al.
Leukemia & Lymphoma|April 16, 2024
Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)Imran Haider, Darryl P Leong, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 20, 2024
First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline ConsortiumSahar Khan, Debra J Bergstrom, Julie Côté, et al.
Blood Cancer Journal|March 27, 2026
Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disordersEdward Koo, Sarah Albert, Benjamin Patrick, et al.
Blood Cancer Journal|October 14, 2024
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myelomaAnnika Werly, Mareike Hampel, Thomas Hielscher, et al.
Cancer Letters|December 26, 2025
Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary diseaseShelby Kaczmarek, Donghyeon Jo, Safa Ghaziasgar, et al.
Frontiers in Immunology|March 24, 2025
Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expressionDong-Hyeon Jo, Shelby Kaczmarek, Abrar Ul Haq Khan, et al.
Cytotherapy|December 18, 2024
Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studiesDonald J Bastin, Marisa K Kilgour, Risa Shorr, et al.
The Oncologist|April 18, 2024
A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple MyelomaHira Mian, Hsien Seow, Amaris K Balitsky, et al.
Pageof 8

Showing results (21-30 of 73) with videos related to

Sort By:
Pageof 8
Journal of Geriatric Oncology|July 21, 2023
Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysisJoanne Britto, Hsien Seow, Gregory R Pond, et al.
Blood Cancer Journal|April 27, 2023
An atlas of the bone marrow bone proteome in patients with dysproteinemiasMatthew Ho, Surendra Dasari, Alissa Visram, et al.
Leukemia & Lymphoma|April 16, 2024
Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)Imran Haider, Darryl P Leong, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 20, 2024
First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline ConsortiumSahar Khan, Debra J Bergstrom, Julie Côté, et al.
Blood Cancer Journal|March 27, 2026
Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disordersEdward Koo, Sarah Albert, Benjamin Patrick, et al.
Blood Cancer Journal|October 14, 2024
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myelomaAnnika Werly, Mareike Hampel, Thomas Hielscher, et al.
Cancer Letters|December 26, 2025
Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary diseaseShelby Kaczmarek, Donghyeon Jo, Safa Ghaziasgar, et al.
Frontiers in Immunology|March 24, 2025
Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expressionDong-Hyeon Jo, Shelby Kaczmarek, Abrar Ul Haq Khan, et al.
Cytotherapy|December 18, 2024
Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studiesDonald J Bastin, Marisa K Kilgour, Risa Shorr, et al.
The Oncologist|April 18, 2024
A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple MyelomaHira Mian, Hsien Seow, Amaris K Balitsky, et al.
Pageof 8